What does Novavax, Inc. do?

Jun 22 2025 06:15 PM IST
share
Share Via
Novavax, Inc. is a clinical-stage vaccine company specializing in recombinant nanoparticle vaccines and adjuvants. As of March 2025, it reported net sales of $667 million and a net profit of $519 million, with a market cap of approximately $1.05 billion.
Overview:
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants within the Pharmaceuticals & Biotechnology industry.

Financial Snapshot:
Most recent Net Sales: 667 Million (Quarterly Results - Mar 2025)
Most recent Net Profit: 519 Million (Quarterly Results - Mar 2025)
Market-cap: USD 1,054.81 Million (Micro Cap)

Key Metrics:
P/E: 2.00
Dividend Yield: 0.00%
Debt Equity: 7.49
Return on Equity: -647.88%
Price to Book: -13.94

Contact Details:
Address: 21 Firstfield Rd, GAITHERSBURG MD: 20878-1757
Tel: 1 240 2682000
Website: http://www.novavax.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News